Funding the future of retinal health with Eyepoint

Hello, and welcome to Pathfinders, podcast series from RBC Capital Markets, where we uncover the key trends and catalysts shaping the fast moving world of biopharma and health care. I'm your host, Joe Colletti. Today, we're streaming from RBC's global health care conference here in New York, and we're gonna be exploring innovative therapeutics intended to improve the lives of patients with serious retinal disease. Joining us is George Elston, chief financial officer and head of corporate development at EyePoint Pharmaceuticals, which is developing groundbreaking programs such as DuraView and EYP twenty three zero one designed to provide patients with better visual outcomes. George is a seasoned financial executive with over thirty years of experience in the biopharma industry, including leadership roles at two x Oncology and Enzavant Therapeutics, culminating in his current position at EyePoint Pharma, where he drives financial strategy and corporate development to help realize the company's ambitious goals. Today, we'll talk about EyePoint's innovative approach to therapeutics, combating retinal disease, their developing programs and trials in a partnership network, and what investors should be looking out for in this exciting and evolving space. George, it's great to have you with us today. Thank you, Joe. Happy to be here. So in light of the macroeconomic environment, how's EyePoint managing its capital allocation priorities right now? Particularly, I wanna hear this from your lens as CFO and head of corporate development, which I think is a is a different angle that we always hear on our episodes. That's an important question on every investor in company's mind. And I think from my point's perspective, we are fortunate that, we are at a very good capital position. We're in two global phase three trials with, Duroview. Those trials are called Lugano and Lucia. They're two global trials. We're expected to have completion of enrollment this year with, top line data readout in the 2026. And importantly for us, we're funded not just through those trials, but into 2027. We ended March with 318,000,000 in cash, and that puts us in a very good place. To your point, it's been a very difficult market. I think the entire space has been under a lot of pressure, including a lot of our investors, but we were fortunate, to have raised capital on, some DME data that we had in 2024 and put us in a really good position forward. I think on the allocation perspective, we've been very focused on the execution. We are a wet AMD story. Our capital is allocated to completion of those wet AMD trials and preparing for an NDA filing, and that includes our commercial manufacturing facility, which is in Northbridge, Massachusetts. So we are not just focused on completing the phase three and get hopefully getting a positive readout, but also completing registration batches, preparing for a preapproval inspection, and ultimately commercial launch. So with the market for retinal disease treatments expanding, how is EyePoint positioning itself to lead the next wave of innovation …